Your session is about to expire
← Back to Search
Trastuzumab Deruxtecan for Gastric Cancer
Study Summary
This trial will find out if trastuzumab deruxtecan is safe and works for people with HER2-positive gastric or gastroesophageal cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: All participants
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the purpose of this research?
"The primary outcome of this study, to be measured over a period of approximately 30 months, is the percentage of participants with an objective response rate (ORR) based on independent central review following treatment with DS8201a in participants with HER2-positive unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma. Additionally, secondary outcomes including duration of response (DoR), progression-free survival (PFS) based on investigator assessment following treatment with DS8201a in participants with HER2-positive unresectable or metastatic gastric or gastro"
What are the odds of negative side effects from Trastuzumab deruxtecan?
"Trastuzumab deruxtecan's place on the 1-3 Power safety scale is a 2. This is due to it being a Phase 2 clinical trial, so while there is some evidence of its safety, none exists for its efficacy."
Can people still sign up for this experiment?
"According to the latest update on clinicaltrials.gov, this trial is not currently recruiting patients. This study was first posted on November 26th, 2019 but has not been updated since August 31st, 2022. There are 824 other trials that are actively looking for patients right now."
How many study participants are there in total?
"As of right now, this trial is not looking for new patients. However, it was updated recently on August 31st, 2022 and was first posted on November 26th, 2019. There are 787 other trials currently underway for adenocarcinoma and 37 involving Trastuzumab deruxtecan if you're interested in finding an active study."
Are there multiple research facilities overseeing this data?
"There are 20 sites running this trial, which include UCLA Health in Santa Monica, USC Norris Comprehensive Cancer Center Hospital in Los Angeles, and Massachusetts General Hospital (MGH) in Boston."
What are the precedent clinical studies for Trastuzumab deruxtecan?
"There are currently 37 separate clinical trials underway for Trastuzumab deruxtecan, 10 of which have reached Phase 3. Though several locations for these trials are in Phoenix, Arizona, there are over 3000 hospitals and research centres around the world testing this medication."
Has this clinical trial been done before?
"As of now, 37 Trastuzumab deruxtecan clinical trials are ongoing in 487 cities across 44 countries. The first-ever trial for this medication was back in 2015 and involved 292 patients. That study reached its Phase 1 drug approval stage and was sponsored by Daiichi Sankyo, Inc. In the years since then, 5 more trials have been completed."
Share this study with friends
Copy Link
Messenger